Related Experiment Video
Updated: Jul 9, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
Insulin pump therapy (continuous subcutaneous insulin infusion)
1Department of Community and Family Medicine, University of Missouri-Kansas City School of Medicine, Truman Medical Center Lakewood, Kansas City, MO 64139, USA. Russell.White@tmcmed.org
Continuous subcutaneous insulin infusion (CSII) offers better diabetes management with less severe hypoglycemia. Future implanted insulin pumps promise near-normal blood sugar control and prevention of long-term diabetes complications.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Biomedical Engineering
Background:
- Continuous subcutaneous insulin infusion (CSII) is a key therapy for diabetes management.
- CSII systems improve treatment target achievement and reduce severe hypoglycemia.
- Patient preference favors CSII for its flexibility, convenience, and physiologic glycemic control.
Purpose of the Study:
- To highlight the benefits of current continuous subcutaneous insulin infusion (CSII) systems.
- To discuss the future of insulin delivery with closed-loop systems.
- To emphasize the potential for near-normal glycemia and prevention of diabetes complications.
Main Methods:
- Review of current literature on continuous subcutaneous insulin infusion (CSII) therapy.
- Analysis of patient-reported outcomes and preferences for CSII.
- Projection of future advancements in insulin pump technology and closed-loop systems.
Main Results:
- CSII systems enable effective glycemic control with a reduced incidence of severe hypoglycemia.
- Patients report high satisfaction with CSII due to improved flexibility and convenience.
- Future implanted, closed-loop systems are expected to further enhance glycemic control.
Conclusions:
- Continuous subcutaneous insulin infusion (CSII) represents a significant advancement in diabetes care.
- Implanted, closed-loop insulin delivery systems hold promise for achieving near-normal glycemia.
- These advanced systems are anticipated to significantly reduce long-term diabetes complications and severe hypoglycemia.
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous Renal Replacement Therapy
